Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 148
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Am Heart Assoc ; 12(24): e029149, 2023 Dec 19.
Artigo em Inglês | MEDLINE | ID: mdl-38084753

RESUMO

BACKGROUND: The influence of fee-for-service reimbursement on cardiac imaging has not been compared with other payment models. Furthermore, variation in ordering practices is not well understood. METHODS AND RESULTS: This retrospective, population-based cohort study using linked administrative data from Alberta, Canada included adults with chronic heart disease (atrial fibrillation, coronary artery disease, and heart failure) seen by cardiac specialists for a new outpatient consultation April 2012 to December 2018. Generalized linear mixed-effects models estimated the association of payment model (including the ability to bill to interpret imaging tests) and the use of cardiac imaging and quantified variation in cardiac imaging. Among 31 685 adults seen by 308 physicians at 136 sites, patients received an observed mean of 0.67 (95% CI, 0.67-0.68) imaging tests per consultation. After adjustment, patients seeing fee-for-service physicians had 2.07 (95% CI, 1.68-2.54) and fee-for-service physicians with ability to interpret had 2.87 (95% CI, 2.16-3.81) times the rate of receiving a test than those seeing salaried physicians. Measured patient, physician, and site effects accounted for 31% of imaging variation and, following adjustment, reduced unexplained site-level variation 40% and physician-level variation 29%. CONCLUSIONS: We identified substantial variation in the use of outpatient cardiac imaging related to physician and site factors. Physician payment models have a significant association with imaging use. Our results raise concern that payment models may influence cardiac imaging practice. Similar methods could be applied to identify the source and magnitude of variation in other health care processes and outcomes.


Assuntos
Planos de Pagamento por Serviço Prestado , Médicos , Adulto , Humanos , Estudos Retrospectivos , Estudos de Coortes , Alberta
2.
JAMA Health Forum ; 4(5): e231127, 2023 05 05.
Artigo em Inglês | MEDLINE | ID: mdl-37234014

RESUMO

Importance: Few interventions are proven to reduce total health care costs, and addressing cost-related nonadherence has the potential to do so. Objective: To determine the effect of eliminating out-of-pocket medication fees on total health care costs. Design, Setting, and Participants: This secondary analysis of a multicenter randomized clinical trial using a prespecified outcome took place across 9 primary care sites in Ontario, Canada (6 in Toronto and 3 in rural areas), where health care services are generally publicly funded. Adult patients (≥18 years old) reporting cost-related nonadherence to medicines in the past 12 months were recruited between June 1, 2016, and April 28, 2017, and followed up until April 28, 2020. Data analysis was completed in 2021. Interventions: Access to a comprehensive list of 128 medicines commonly prescribed in ambulatory care with no out-of-pocket costs for 3 years vs usual medicine access. Main Outcome and Measures: Total publicly funded health care costs over 3 years, including costs of hospitalizations. Health care costs were determined using administrative data from Ontario's single-payer health care system, and all costs are reported in Canadian dollars with adjustments for inflation. Results: A total of 747 participants from 9 primary care sites were included in the analysis (mean [SD] age, 51 [14] years; 421 [56.4%] female). Free medicine distribution was associated with a lower median total health care spending over 3 years of $1641 (95% CI, $454-$2792; P = .006). Mean total spending was $4465 (95% CI, -$944 to $9874) lower over the 3-year period. Conclusions and Relevance: In this secondary analysis of a randomized clinical trial, eliminating out-of-pocket medication expenses for patients with cost-related nonadherence in primary care was associated with lower health care spending over 3 years. These findings suggest that eliminating out-of-pocket medication costs for patients could reduce overall costs of health care. Trial Registration: ClinicalTrials.gov Identifier: NCT02744963.


Assuntos
Custos de Cuidados de Saúde , Hospitalização , Adulto , Humanos , Feminino , Pessoa de Meia-Idade , Adolescente , Masculino , Atenção à Saúde , Gastos em Saúde , Ontário
3.
Can J Anaesth ; 69(11): 1399-1404, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-35879485

RESUMO

PURPOSE: SARS-CoV-2 vaccines have been proven effective at preventing poor outcomes from COVID-19; however, voluntary vaccination rates have been suboptimal. We assessed the potential avoidable intensive care unit (ICU) resource use and associated costs had unvaccinated or partially vaccinated patients hospitalized with COVID-19 been fully vaccinated. METHODS: We conducted a retrospective, population-based cohort study of persons aged 12 yr or greater in Alberta (2021 population ~ 4.4 million) admitted to any ICU with COVID-19 from 6 September 2021 to 4 January 2022. We used publicly available aggregate data on COVID-19 infections, vaccination status, and health services use. Intensive care unit admissions, bed-days, lengths of stay, and costs were estimated for patients with COVID-19 and stratified by vaccination status. RESULTS: In total, 1,053 patients admitted to the ICU with COVID-19 were unvaccinated, 42 were partially vaccinated, and 173 were fully vaccinated (cumulative incidence 230.6, 30.8, and 5.5 patients/100,000 population, respectively). Cumulative incidence rate ratios of ICU admission were 42.2 (95% confidence interval [CI], 39.7 to 44.9) for unvaccinated patients and 5.6 (95% CI, 4.1 to 7.6) for partially vaccinated patients when compared with fully vaccinated patients. During the study period, 1,028 avoidable ICU admissions and 13,015 bed-days were recorded for unvaccinated patients and the total avoidable costs were CAD 61.3 million. The largest opportunity to avoid ICU bed-days and costs was in unvaccinated patients aged 50 to 69 yr. CONCLUSIONS: Unvaccinated patients with COVID-19 had substantially greater rates of ICU admissions, ICU bed-days, and ICU-related costs than vaccinated patients did. This increased resource use would have been potentially avoidable had these unvaccinated patients been vaccinated against SARS-CoV-2.


RéSUMé: OBJECTIF: Les vaccins contre le SRAS-CoV-2 se sont avérés efficaces pour prévenir les devenirs défavorables associés à la COVID-19; toutefois, les taux de vaccination volontaire ont été sous-optimaux. Nous avons évalué l'utilisation potentiellement évitable des ressources des unités de soins intensifs (USI) et les coûts associés si les patients non vaccinés ou partiellement vaccinés qui ont dû être hospitalisés pour la COVID-19 avaient été complètement vaccinés. MéTHODE: Nous avons réalisé une étude de cohorte rétrospective basée sur la population de personnes âgées de 12 ans ou plus en Alberta (population de 2021 ~ 4,4 millions) admises dans une unité de soins intensifs et atteintes de COVID-19 du 6 septembre 2021 au 4 janvier 2022. Nous avons utilisé des données agrégées accessibles au public sur les infections à la COVID-19, le statut vaccinal et l'utilisation des services de santé. Les admissions aux soins intensifs, les journées-patients, les durées de séjour et les coûts ont été estimés pour les patients atteints de la COVID-19 et stratifiés selon le statut vaccinal. RéSULTATS: Au total, 1053 patients admis à l'USI souffrant de la COVID-19 n'étaient pas vaccinés, 42 étaient partiellement vaccinés et 173 étaient complètement vaccinés (incidence cumulative 230,6, 30,8 et 5,5 patients / 100 000 habitants, respectivement). Les taux d'incidence cumulés des admissions aux soins intensifs étaient de 42,2 (intervalle de confiance [IC] à 95 %, 39,7 à 44,9) pour les patients non vaccinés et de 5,6 (IC 95 %, 4,1 à 7,6) pour les patients partiellement vaccinés par rapport aux patients entièrement vaccinés. Au cours de la période à l'étude, 1028 admissions évitables aux soins intensifs et 13 015 journées-patients ont été enregistrées pour les patients non vaccinés, et les coûts totaux évitables étaient de 61,3 millions de dollars canadiens. L'économie potentielle la plus importante en matière de journées-patients et de coûts en soins intensifs touchait les patients non vaccinés âgés de 50 à 69 ans. CONCLUSION: Les patients non vaccinés atteints de COVID-19 ont affiché des taux beaucoup plus élevés d'admissions à l'USI, de journées-patients à l'USI et de coûts liés à l'USI que les patients vaccinés. Cette utilisation accrue des ressources aurait été potentiellement évitable si ces patients non vaccinés avaient été vaccinés contre le SRAS-CoV-2.


Assuntos
COVID-19 , Humanos , Estudos de Coortes , COVID-19/prevenção & controle , Estudos Retrospectivos , Vacinas contra COVID-19 , SARS-CoV-2 , Unidades de Terapia Intensiva
4.
CMAJ Open ; 10(3): E577-E588, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35790226

RESUMO

BACKGROUND: The growing burden associated with population aging, dementia and multimorbidity poses potential challenges for the sustainability of health systems worldwide. We sought to examine how the intersection among age, dementia and greater multimorbidity is associated with health care costs. METHODS: We did a retrospective population-based cohort study in Alberta, Canada, with adults aged 65 years and older between April 2003 and March 2017. We identified 31 morbidities using algorithms (30 algorithms were validated), which were applied to administrative health data, and assessed costs associated with hospital admission, provider billing, ambulatory care, medications and long-term care (LTC). Actual costs were used for provider billing and medications; estimated costs for inpatient and ambulatory patients were based on the Canadian Institute for Health Information's resource intensive weights and Alberta's cost of a standard hospital stay. Costs for LTC were based on an estimated average daily cost. RESULTS: There were 827 947 people in the cohort. Dementia was associated with higher mean annual total costs and individual mean component costs for almost all age categories and number of comorbidities categories (differences in total costs ranged from $27 598 to $54 171). Similarly, increasing number of morbidities was associated with higher mean total costs and component costs (differences in total costs ranged from $4597 to $10 655 per morbidity). Increasing age was associated with higher total costs for people with and without dementia, driven by increasing LTC costs (differences in LTC costs ranged from $115 to $9304 per age category). However, there were no consistent trends between age and non-LTC costs among people with dementia. When costs attributable to LTC were excluded, older age tended to be associated with lower costs among people with dementia (differences in non-LTC costs ranged from -$857 to -$7365 per age category). INTERPRETATION: Multimorbidity, older age and dementia were all associated with increased use of LTC and thus health care costs, but some costs among people with dementia decreased at older ages. These findings illustrate the complexity of projecting the economic consequences of the aging population, which must account for the interplay between multimorbidity and dementia.


Assuntos
Demência , Multimorbidade , Adulto , Idoso , Alberta/epidemiologia , Estudos de Coortes , Demência/epidemiologia , Demência/terapia , Custos de Cuidados de Saúde , Humanos , Estudos Retrospectivos
5.
CMAJ Open ; 10(2): E390-E399, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35440486

RESUMO

BACKGROUND: Few studies have categorized high-cost patients (defined by accumulated health care spending above a predetermined percentile) into distinctive groups for which potentially actionable interventions may improve outcomes and reduce costs. We sought to identify homogeneous groups within the persistently high-cost population to develop a taxonomy of subgroups that may be targetable with specific interventions. METHODS: We conducted a retrospective analysis in which we identified adults (≥ 18 yr) who lived in Alberta between April 2014 and March 2019. We defined "persistently high-cost users" as those in the top 1% of health care spending across 4 data sources (the Discharge Abstract Database for inpatient encounters; Practitioner Claims for outpatient primary care and specialist encounters; the Ambulatory Care Classification System for emergency department encounters; and the Pharmaceutical Information Network for medication use) in at least 2 consecutive fiscal years. We used latent class analysis and expert clinical opinion in tandem to separate the persistently high-cost population into subgroups that may be targeted by specific interventions based on their distinctive clinical profiles and the drivers of their health system use and costs. RESULTS: Of the 3 919 388 adults who lived in Alberta for at least 2 consecutive fiscal years during the study period, 21 115 (0.5%) were persistently high-cost users. We identified 9 subgroups in this population: people with cardiovascular disease (n = 4537; 21.5%); people receiving rehabilitation after surgery or recovering from complications of surgery (n = 3380; 16.0%); people with severe mental health conditions (n = 3060; 14.5%); people with advanced chronic kidney disease (n = 2689; 12.7%); people receiving biologic therapies for autoimmune conditions (n = 2538; 12.0%); people with dementia and awaiting community placement (n = 2520; 11.9%); people with chronic obstructive pulmonary disease or other respiratory conditions (n = 984; 4.7%); people receiving treatment for cancer (n = 832; 3.9%); and people with unstable housing situations or substance use disorders (n = 575; 2.7%). INTERPRETATION: Using latent class analysis supplemented with expert clinical review, we identified 9 policy-relevant subgroups among persistently high-cost health care users. This taxonomy may be used to inform policy, including identifying interventions that are most likely to improve care and reduce cost for each subgroup.


Assuntos
Transtornos Mentais , Alta do Paciente , Adulto , Assistência Ambulatorial , Atenção à Saúde , Humanos , Estudos Retrospectivos
6.
Cancer Treat Res Commun ; 29: 100495, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34875463

RESUMO

OBJECTIVES: Early diagnosis of lung cancer increases the chance of survival. The aim of this study was to measure the relationship between geographic residence in Saskatchewan and stage of lung cancer at the time of diagnosis. MATERIALS AND METHODS: Retrospective cohort analysis of 2,972 patients with a primary diagnosis of either non-small cell cancer (NSCLC) or small cell lung cancer (SCLC) between 2007 and 2012 was performed. Incidence proportion of early and advanced stage cancer, and relative risk of being diagnosed with advanced-stage lung cancer relative to early-stage was calculated. RESULTS: Compared to urban Saskatchewan, rural Saskatchewan lung cancer patients had a higher relative risk of advanced stage NSCLC (relative risk [RR] = 1.11, 95% confidence interval [CI]: 1.01-1.22). Rural Saskatchewan was further subdivided into north and south. The relative risk of advanced stage NSCLC in rural north Saskatchewan compared to urban Saskatchewan was even greater (RR = 1.17, 95% CI: 1.03-1.31). Although not statistically significant, there was a trend for a higher incidence of advanced stage SCLC in rural and rural north vs urban Saskatchewan (RR = 1.16, 95% CI: 0.95-1.43 and RR = 1.22; 95% CI: 0.94-1.58, respectively). There was a higher incidence proportion of advanced stage NSCLC in rural areas relative to urban (31.6-34.4 vs 29.5 per 10,000 people). CONCLUSION: Patients living in rural Saskatchewan have higher incidence proportion of and were more likely to present with advanced stage NSCLC in comparison to urban Saskatchewan patients at time of diagnosis. This inequality was even greater in rural north Saskatchewan.


Assuntos
Neoplasias Pulmonares/epidemiologia , Idoso , Feminino , Humanos , Neoplasias Pulmonares/mortalidade , Masculino , Estadiamento de Neoplasias , População Rural , Análise de Sobrevida , População Urbana
7.
CMAJ Open ; 9(3): E788-E794, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34285058

RESUMO

BACKGROUND: Despite well-documented challenges in recruiting physicians to rural practice, few Canadian studies have described the role physician payment models may play in attracting and retaining physicians to rural practice. This study examined the perspectives of rural primary care physicians on the factors that attract and retain physicians in rural locations, including the role that alternative payment models (APMs) might play. METHODS: This was a qualitative study involving in-depth, open-ended interviews with rural primary care physicians practising under fee-for-service (FFS) models and APMs in Alberta, Canada. Participants were recruited from the Rural Health Professions Action Plan member list (consisting of physicians practising in rural or remote locations in Alberta) and the College of Physicians and Surgeons of Alberta online database. Interviews were conducted April to June 2020, and data were analyzed using a thematic framework approach. RESULTS: Fourteen physicians were interviewed. There were 5 themes identified: factors that attract physicians to rural practice, barriers and challenges associated with rural practice, the potential role of APMs in recruitment and retention, factors that physicians consider in deciding to change payment models, and physician perceptions of APMs compared with FFS models. Participants expressed that APMs may have some role to play in retaining rural physicians but identified professional challenges, and family-related and personal factors as key determinants. Most FFS physicians indicated that they were interested in exploring APMs provided specific concerns were addressed (e.g., clear and adequately compensated APM contracts, and physician involvement in the development of APMs). INTERPRETATION: Primary care physicians practising in rural regions in Alberta view payment models as one consideration among many in their decision to pursue rural practice. Alternative payment model contracts designed with the input of physicians may have a role to play in attracting and retaining physicians to rural practice.


Assuntos
Atitude do Pessoal de Saúde , Planos de Pagamento por Serviço Prestado/estatística & dados numéricos , Papel do Médico , Médicos de Atenção Primária/psicologia , Mecanismo de Reembolso/estatística & dados numéricos , Serviços de Saúde Rural/estatística & dados numéricos , Alberta/epidemiologia , Tomada de Decisões , Análise Fatorial , Feminino , Humanos , Masculino , Pesquisa Qualitativa , Fatores de Risco
8.
Can J Kidney Health Dis ; 8: 20543581211018528, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34158964

RESUMO

BACKGROUND: Prior studies report high hospitalization rates among patients with chronic kidney disease (CKD) and approximately 10% to 20.9% of hospitalizations are potentially preventable. OBJECTIVE: To determine the rate, proportion, and cost of potentially preventable hospitalizations and whether this varied by CKD category. DESIGN: Retrospective cohort study using population-based data. SETTING: Alberta, Canada. PATIENTS: All adults with an outpatient serum creatinine measurement between January 1 and December 31, 2017 in the Alberta Kidney Disease Network data repository. MEASUREMENTS: CKD risk categories were based on measures of proteinuria (where available), eGFR, and use of dialysis. Patients were linked to administrative data to capture frequency and cost of hospital encounters and followed until death or end of study (December 31, 2018). The outcomes of interest were the rate and cost of potentially preventable hospitalizations, as identified using the Canadian Institute for Health Information (CIHI)-defined ambulatory care sensitive condition (ACSC) algorithm and a CKD-related ACSC algorithm. METHODS: Unadjusted and adjusted rates per 1000-patient years, proportions, and cost attributable to preventable hospitalizations were identified for the cohort as a whole and for patients within each CKD risk category. RESULTS: Of the 1,110,895 adults with eGFR and proteinuria measurements, 181,422 had CKD. During a median follow-up of 1 year, there were 62,023 hospitalizations among patients with CKD resulting in a total cost of $946 million CAD; 6907 (11.1%) of these hospitalizations were for CIHI-defined ACSCs while 4323 (7.0%) were for CKD-related ACSCs. Adjusted rates of hospitalization for ACSCs increased with CKD risk category and were highest among patients treated with dialysis. Among CKD patients, the total cost of potentially preventable hospitalizations was $79 million and $58 million CAD for CIHI-defined and CKD-related ACSCs (8.4% and 6.2% of total hospitalization cost, respectively). LIMITATIONS: Based on the ACSC construct, we were unable to determine if these hospitalizations were truly preventable. CONCLUSIONS: Potentially preventable hospitalizations have a substantial cost and burden on the health care system among people with CKD. Effective strategies that reduce preventable admissions among CKD patients may lead to significant cost savings. TRIAL REGISTRATION: Not applicable-observational study design.


CONTEXTE: Des études antérieures font état de taux élevés d'hospitalization chez les patients atteints d'insuffisance rénale chronique (IRC). Environ 10% à 20,9 % de ces hospitalisations seraient évitables. OBJECTIFS: Établir l'incidence et la proportion des hospitalisations potentiellement évitables, de même que les coûts qui y sont attribuables, et vérifier si cela varie en fonction de la catégorie d'IRC. TYPE D'ÉTUDE: Étude de cohorte rétrospective menée à partir de données basées sur une population. CADRE: Alberta, Canada. SUJETS: Tous les adultes pour qui le référentiel de données du Alberta Kidney Disease Network disposait d'une mesure de créatinine sérique en consultation externe entre le 1er janvier et le 31 décembre 2017. MESURES: La mesure de protéinurie (lorsque disponible), le DFGe et la dialyze ont servi à établir les catégories de risque d'IRC. Les patients ont été couplés aux données administratives afin de saisir la fréquence des consultations à l'hôpital et le coût associé à celles-ci. Le suivi s'est poursuivi jusqu'au décès du patient ou jusqu'au 31 décembre 2018 (fin de l'étude). Les critères d'intérêt étaient l'incidence des hospitalisations évitables, de même que les coûts qui y sont attribuables; hospitalisations définies par l'algorithme de l'Institut canadien d'information sur la santé (ICIS) pour les conditions propices aux soins ambulatoires (CPSA) et par un algorithme des CPSA liées à l'IRC. MÉTHODOLOGIE: Les taux corrigés ou non pour 1000 années-patients et les proportions des hospitalisations évitables, de même que les coûts qui y sont attribuables, ont été déterminés pour l'ensemble de la cohorte et pour les patients de chaque catégorie de risque d'IRC. RÉSULTATS: Parmi les 1 110 895 adultes disposant de mesures de protéinurie et de DFGe, 181 422 étaient atteints d'IRC. Au cours d'un suivi médian d'un an, on a répertorié 62 023 hospitalisations de patients atteints d'IRC, ce qui représente un coût total de 946 millions de dollars canadiens. De ces hospitalisations, 6 907 (11,1 %) concernaient des CPSA définies par l'ICIS et 4 323 (7,0 %) concernaient des CPSA liées à l'IRC. Les taux corrigés d'hospitalization pour les CPSA augmentaient selon la catégorie de risque d'IRC et étaient plus élevés chez les patients dialysés. Chez les patients atteints d'IRC, le coût total des hospitalisations évitables s'établissait à 79 millions de dollars pour les CPSA définies par l'ICIS et à 58 millions de dollars canadiens pour les CPSA liées à l'IRC (respectivement 8,4 % et 6,2 % du coût total attribuable aux hospitalisations). LIMITES: La structure des CPSA ne nous a pas permis de déterminer si ces hospitalisations étaient effectivement évitables. CONCLUSION: Les hospitalisations évitables chez les patients atteints d'IRC représentent un fardeau et des coûts considérables pour le système de santé. Des stratégies efficaces qui permettraient de les réduire chez les patients atteints d'IRC entraîneraient des économies substantielles.

9.
CJC Open ; 3(6): 703-713, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-34169249

RESUMO

BACKGROUND: A range of first-line similarly effective medications ranging in price are recommended for treating uncomplicated hypertension. Considering drug costs alone, thiazides and thiazide-like diuretics are the most cost-efficient option. We determined incident prescribing of thiazides for newly diagnosed hypertension as first-line treatment in Alberta, factors that predicted receiving thiazides vs more costly medications, and how much could be saved if more patients were prescribed thiazides. METHODS: Using a retrospective cohort design, factors predicting receiving thiazides vs other agents were determined using mixed effects logistic regression. Cost savings were simulated by shifting patients from other antihypertensive medications to thiazides and calculating the difference. RESULTS: Within our cohort of 89,548 adults, only 12% received thiazides as first-line treatment whereas 44% received angiotensin converting enzyme inhibitors, 17% received angiotensin receptor blockers, 16% received calcium channel blockers, and 10% received ß-blockers. Antihypertensive medications were typically prescribed by office-based, general practitioners (88%). Being male and receiving a prescription from a physician with ≥ 20 years of practice and a high clinical workload were associated with increased odds of receiving nonthiazides. In the extreme case that all patients received thiazides as their first prescription, spending would have been reduced by a maximum of 95% (CAD$1.8 million). CONCLUSIONS: Only 12% of Albertan adults with incident, uncomplicated hypertension were prescribed thiazides as first-line treatment. With the opportunity for drug cost savings, future research should evaluate the risk of adverse events and side effects across the drug classes and whether the costs associated with managing those risks could offset the savings achieved through increased thiazide use.


CONTEXTE: De nombreux médicaments tous aussi efficaces les uns que les autres, mais de prix variable, sont recommandés pour le traitement de première intention de l'hypertension non compliquée. Si l'on tient compte du coût du médicament seulement, les thiazides et les diurétiques apparentés aux thiazides sont les options les plus économiques. Nous avons évalué le taux de prescription d'un thiazide pour le traitement de première intention de l'hypertension nouvellement diagnostiquée en Alberta, les facteurs de prédiction de la prescription d'un thiazide plutôt que d'un autre médicament plus coûteux, ainsi que les économies qui pourraient être réalisées si on prescrivait un thiazide à un plus grand nombre de patients. MÉTHODOLOGIE: Dans le cadre de notre étude de cohorte rétrospective, nous avons déterminé les facteurs de prédiction de la prescription d'un thiazide plutôt que d'un autre agent à l'aide d'une régression logistique à effets mixtes. Nous avons simulé les économies qui pourraient être réalisées en faisant passer à un thiazide les patients à qui un autre médicament antihypertenseur a été prescrit et en calculant la différence. RÉSULTATS: Dans notre cohorte de 89 548 adultes, seulement 12 % des patients ont reçu un thiazide en première intention; 44 % ont reçu un inhibiteur de l'enzyme de conversion de l'angiotensine; 17 %, un antagoniste des récepteurs de l'angiotensine; 16 %, un inhibiteur calcique; et 10 %, des bêtabloquants. Les agents antihypertenseurs sont généralement prescrits par des omnipraticiens en cabinet (88 %). Le fait d'être un homme et le fait d'obtenir une prescription auprès d'un médecin exerçant depuis au moins 20 ans et ayant une lourde charge de travail clinique étaient associés à une probabilité supérieure de recevoir un agent autre qu'un thiazide. Dans le cas extrême où tous les patients se verraient prescrire un thiazide en première intention, la réduction des dépenses pourrait atteindre 95 % (soit 1,8 million de dollars canadiens). CONCLUSIONS: En Alberta, un thiazide a été prescrit en première intention à seulement 12 % des adultes venant de recevoir un diagnostic d'hypertension non compliquée. Compte tenu des économies qui pourraient être réalisées si un thiazide était prescrit dans ce contexte, il conviendrait d'effectuer des recherches plus poussées pour évaluer le risque de manifestations indésirables et d'effets secondaires associé aux différentes classes de médicaments, et pour déterminer si les coûts liés à la prise en charge de ce risque annuleraient les économies réalisées en augmentant le recours aux thiazides.

10.
Diabet Med ; 38(9): e14622, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34133781

RESUMO

AIMS: To use real-world prescription data from Alberta, Canada to: (a) describe the prescribing patterns for initial pharmacotherapy for those with newly diagnosed uncomplicated type 2 diabetes; (b) describe medication-taking behaviours (adherence and persistence) in the first year after initiating pharmacotherapy; and (c) explore healthcare system costs associated with prescribing patterns. METHODS: We employed a retrospective cohort design using linked administrative datasets from 2012 to 2017 to define a cohort of those with uncomplicated incident diabetes. We summarized the initial prescription patterns, adherence and costs (healthcare and pharmaceutical) over the first year after initiation of pharmacotherapy. Using multivariable regression, we determined the association of these outcomes with various sociodemographic characteristics. RESULTS: The majority of individuals for whom metformin was indicated as first-line therapy received a prescription for metformin monotherapy (89%). Older individuals, those with higher baseline A1C and those with no comorbidities, were most likely to be started on non-metformin agents. Adherence with the initially prescribed regimen was suboptimal overall, with nearly half (48%) being non-adherent over the first year. One-third of those who started metformin discontinued it in the first 3 months. Those started on non-metformin agents had roughly twice the healthcare costs, and five to seven times higher medication costs, compared to those started on metformin, in the first year after starting therapy. CONCLUSIONS: With the addition of new classes of medications, healthcare providers who look after those with type 2 diabetes have more pharmaceutical options than ever. Most individuals continue to be prescribed metformin monotherapy. However, adherence is suboptimal, and drops off considerably within the first 3 months.


Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Custos de Medicamentos , Custos de Cuidados de Saúde/tendências , Adesão à Medicação , Metformina/uso terapêutico , Prescrições/estatística & dados numéricos , Adolescente , Adulto , Idoso , Alberta/epidemiologia , Diabetes Mellitus Tipo 2/economia , Diabetes Mellitus Tipo 2/epidemiologia , Feminino , Seguimentos , Humanos , Hipoglicemiantes/uso terapêutico , Masculino , Pessoa de Meia-Idade , Morbidade/tendências , Estudos Retrospectivos , Adulto Jovem
11.
Methods Mol Biol ; 2249: 501-516, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33871861

RESUMO

The pressure for health-care systems to provide more resource-intensive health care and newer more costly therapies is significant, despite limited health-care budgets. As such, demonstration that a new therapy is effective is no longer sufficient to ensure that it is funded within publicly funded health-care systems. The impact of a therapy on health-care costs is also an important consideration for decision makers who must allocate scarce resources. The clinical benefits and costs of a new therapy can be estimated simultaneously using economic evaluation; the strengths and limitations of which are discussed herein. In addition, within this chapter, we discuss the important economic outcomes that can be collected within a clinical trial (alongside the clinical outcome data) enabling consideration of the impact of the therapy on overall resource use, thus enabling performance of an economic evaluation, if the therapy is shown to be effective.


Assuntos
Tomada de Decisão Clínica/métodos , Ensaios Clínicos como Assunto/economia , Medicina Baseada em Evidências/economia , Análise Custo-Benefício , Custos de Cuidados de Saúde , Humanos , Saúde Pública/economia
12.
Europace ; 23(5): 767-774, 2021 05 21.
Artigo em Inglês | MEDLINE | ID: mdl-33554239

RESUMO

AIMS: Recent evidence suggests that an antibiotic impregnated envelope inserted at time of cardiac implantable electronic device (CIED) implantation may reduce risk of subsequent CIED infection compared with standard of care (SoC). The objective of the current work was to perform a cost-effectiveness analysis comparing an antibiotic impregnated envelope with SoC at time of CIED insertion. METHODS AND RESULTS: Decision analytic models were used to project healthcare costs and benefits of two strategies, an antibiotic impregnated envelope plus SoC (Env+SoC) vs. SoC alone, in a cohort of patients undergoing CIED implantation over a 1-year time horizon. Evidence from published literature informed the model inputs. Probabilistic and deterministic sensitivity analyses were performed. The primary outcome was the incremental cost per infection prevented, assessed from the Canadian healthcare system perspective. Envelope plus SoC was associated with fewer CIED infection (7 CIED infections/1000 patients) at higher total costs ($29 033 000/1000 patients) compared with SoC (11 CIED infections and $27 926 000/1000 patients). The incremental cost per infection prevented over 1 year was $274 416. Use of Env+SoC was cost saving only when baseline CIED infection risk was increased to 6% (vs. base case of 1.2%). CONCLUSIONS: A strategy of Env+SoC was not economically favourable compared with SoC alone, and the opportunity cost of widescale implementation should be considered. Future work is required to develop validated risk stratification tools to identify patients at greatest risk of CIED infection. The value proposition of Env+SoC improves when applying this intervention to patients at greatest infection risk.


Assuntos
Desfibriladores Implantáveis , Infecções Relacionadas à Prótese , Antibacterianos/efeitos adversos , Canadá , Análise Custo-Benefício , Desfibriladores Implantáveis/efeitos adversos , Eletrônica , Humanos , Infecções Relacionadas à Prótese/diagnóstico , Infecções Relacionadas à Prótese/epidemiologia , Infecções Relacionadas à Prótese/prevenção & controle
13.
Health Policy ; 125(4): 442-449, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33509635

RESUMO

Most physicians across the world are paid through fee-for-service. However, there is increased interest in alternative payment models such as salary, capitation, episode-based payment, pay-for-performance, and strategic blends of these models. Such models may be more aligned with broad health policy goals such as fiscal sustainability, delivery of high-quality care, and physician and patient well-being. Despite this, there is limited research on physicians' preferences for different models and a disproportionate focus on differences in income over other issues such as physician autonomy and purpose. Using qualitative interviews with 32 specialist physicians in Alberta, Canada, we examined factors that influence preferences for fee-for-service (FFS) and salary-based payment models. Our findings suggest that a series of factors relating to (1) physician characteristics, (2) payment model characteristics, and (3) professional interests influence preferences. Within these themes, flexibility, autonomy, and compatibility with academic roles were highlighted. To encourage physicians to select a specific payment model, the model must appeal to them in terms of income potential as well as non-monetary values. These findings can support constructive discussions about the merits of different payment models and can assist policy makers in considering the impact of payment reform.


Assuntos
Médicos , Reembolso de Incentivo , Alberta , Capitação , Planos de Pagamento por Serviço Prestado , Humanos , Salários e Benefícios
14.
Arthritis Care Res (Hoboken) ; 73(2): 266-274, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-31733035

RESUMO

OBJECTIVE: Screening psoriasis patients for psoriatic arthritis (PsA) is intended to identify patients at earlier stages of the disease. Early treatment is expected to slow disease progression and delay the need for biologic therapy. Our objective was to determine the cost-effectiveness of screening for PsA in patients with psoriasis in Canada. METHODS: A Markov model was built to estimate the costs and quality-adjusted life years (QALYs) of screening tools for PsA in psoriasis patients. The screening tools included the Toronto Psoriatic Arthritis Screen, Psoriasis Epidemiology Screening Tool, Psoriatic Arthritis Screening and Evaluation, and Early Psoriatic Arthritis Screening Questionnaire (EARP) questionnaires. States of health were defined by disability levels as measured by the Health Assessment Questionnaire. State transitions were modeled based on annual disease progression. Incremental cost-effectiveness ratios and incremental net monetary benefits were estimated. Sensitivity analyses were undertaken to account for parameter uncertainty and to test model assumptions. RESULTS: Screening was cost-effective compared to no screening. The EARP tool had the lowest total cost ($2,000 per patient per year saved compared to no screening) and the highest total QALYs (additional 0.18 per patient compared to no screening). The results were most sensitive to test accuracy and the efficacy of disease-modifying antirheumatic drugs (DMARDs). No screening was cost-effective (at $50,000 per QALY) relative to screening when DMARDs failed to slow disease progression. CONCLUSION: If early therapy with DMARDs delays biologic treatment, implementing screening in patients with psoriasis in Canada is expected to represent a cost savings of $220 million per year and improve the quality of life.


Assuntos
Artrite Psoriásica/diagnóstico , Artrite Psoriásica/economia , Programas de Triagem Diagnóstica/economia , Custos de Cuidados de Saúde , Psoríase/diagnóstico , Psoríase/economia , Inquéritos e Questionários/economia , Antirreumáticos/economia , Antirreumáticos/uso terapêutico , Artrite Psoriásica/tratamento farmacológico , Produtos Biológicos/economia , Produtos Biológicos/uso terapêutico , Redução de Custos , Análise Custo-Benefício , Avaliação da Deficiência , Custos de Medicamentos , Diagnóstico Precoce , Feminino , Humanos , Masculino , Cadeias de Markov , Pessoa de Meia-Idade , Modelos Econômicos , Valor Preditivo dos Testes , Psoríase/tratamento farmacológico , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida
15.
Can J Kidney Health Dis ; 8: 20543581211063984, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-35186304

RESUMO

BACKGROUND: Intravenous (IV) iron and erythropoietin stimulating agents (ESAs) are standard treatments for anemia in patients receiving maintenance hemodialysis. These medications are associated with significant costs to hemodialysis programs and patients. Recent trial evidence demonstrated that a high-dose IV iron protocol reduces ESA usage and improves cardiovascular outcomes. The cost of implementing a high-dose iron protocol within the Canadian public healthcare context remains unknown. OBJECTIVE: Our primary aim was to estimate the costs of a high-dose IV iron protocol in a large Canadian hemodialysis program that currently uses a low-dose and reactive IV iron strategy. Our secondary aim was to estimate the reduction in ESA use required to maintain cost neutrality with a high-dose IV iron protocol. DESIGN: In this modeling study of IV iron and ESA utilization from a regional hemodialysis program, changes in medication utilization were calculated based on observed effects from published trial data. Using data from a quality improvement audit of regional anemia management and medication utilization, we estimated potential cost differences under various modeling conditions. SETTING: Four adult hospital-based and 9 community in-center hemodialysis units in the Alberta Kidney Care-South renal program during the observation period of September 1, 2018, to November 30, 2018. PATIENTS: In total, data from 826 patients were included. MEASUREMENTS: Mean monthly IV iron and ESA doses were obtained from routine audit data captured within an electronic medical record. Costs were determined from provincially negotiated medication prices. METHODS: Current IV iron and erythropoietin dosages were aggregated at the hemodialysis unit level. We used the results from the PIVOTAL trial to estimate the expected increase in IV iron dose and reduction in ESA dose with a high-dose IV iron protocol. We assumed the split between various manufactures of IV iron and ESA were maintained in our cost model. Total medication costs were aggregated by hemodialysis unit, and the mean costs in each unit were used to estimate per-patient costs. Sensitivity analyses included models that assumed 100% IV iron sucrose usage, as well as models where community hemodialysis units and hospital-based hemodialysis units were examined separately. Finally, we calculated a break-even point for ESA dose reduction required to maintain cost neutrality. RESULTS: Actual baseline IV iron and ESA dose utilization across 13 adult HD units were 118 mg/patient/month (95% confidence interval [CI]: 102-134 mg) and 20,764 IU/pt./mo. (95% CI: 18,104-23,424 IU), respectively. The mean combined cost of ESA and IV iron was $315/pt./mo. (95% CI: $274-$355). In comparison, using the results of the PIVOTAL trial and assuming a high-dose IV iron scenario, we estimated mean IV iron use of 215 mg/pt./mo. (95% CI: 187-243 mg/pt./mo.) and a reduction in mean ESA use to 15,923 IU/pt./mo. (95% CI: 13,883-17,962 IU/pt./mo.). This resulted in an estimated cost savings of $38/pt./mo. (95% CI: $33-$42/pt./mo.) and a total program savings of $370,000 per year (95% CI: $325,000-$420,000). Sensitivity analyses under various alternate conditions also showed potential cost savings. We estimated that a dose reduction of ESA of 10% would be required for cost neutrality with a high-dose IV iron protocol. LIMITATIONS: Our study is limited in its use of data from a single randomized controlled trial (RCT) to estimate cost savings rather than actualized utilization. Our models do not take into consideration anticipated reductions in transfusions and hospitalizations that could be realized from a high-dose IV iron protocol. CONCLUSIONS: Based on cost modeling, a high-dose IV iron protocol could be integrated in large Canadian regional hemodialysis program in a cost saving manner. Programs implementing such a protocol should monitor IV iron and EPO use prospectively to determine if the trial protocol as applied in a real-world setting translates into cost savings.


CONTEXTE: Le traitement habituel pour soigner l'anémie chez les patients sous hémodialyse d'entretien consiste en l'administration d'un supplément de fer par voie intraveineuse (IV) et d'agents de stimulation de l'érythropoïétine (ASE); des médicaments coûteux pour les programs d'hémodialyse et les patients. Des études récentes ont démontré qu'un protocole de fer IV à dose élevée réduisait l'utilization des ASE et améliorait les résultats cardiovasculaires. On ignore toutefois les coûts associés à la mise en œuvre d'un tel protocole dans le système public canadien. OBJECTIFS: Notre principal objectif était d'estimer les coûts d'un protocole de fer IV à dose élevée dans un program majeur d'hémodialyse canadien utilisant une stratégie d'administration de fer IV à faible dose et réactive. Nous souhaitions également estimer le taux de réduction de l'utilization des ASE permettant de maintenir la neutralité des coûts avec un protocole de fer IV à dose élevée. CONCEPTION: Dans cette étude de modélisation, où l'administration de fer IV et d'ASE a été examinée dans le cadre d'un program régional d'hémodialyse, les changements dans l'utilization des médicaments ont été calculés en fonction des effets observés à partir des données publiées. Les potentielles différences de coûts ont été estimées dans diverses conditions de modélisation à l'aide des données d'un audit mesurant l'amélioration de la qualité de la gestion de l'anémie et l'utilization des médicaments au niveau régional. CADRE: Quatre unités d'hémodialyse pour adultes en milieu hospitalier et neuf centers d'hémodialyse communautaires du program Alberta Kidney Care ­ South Renal entre le 1er septembre 2018 et le 30 novembre 2018. SUJETS: Les données de 826 patients ont été incluses. MESURES: Les doses moyennes mensuelles de fer IV et d'ASE ont été obtenues avec les données d'un audit courant tirées d'un dossier médical électronique. Les coûts ont été évalués avec les prix négociés par la province pour ces médicaments. MÉTHODOLOGIE: Les posologies actuelles de fer IV et d'érythropoïétine ont été agrégées au niveau de l'unité d'hémodialyse. Les résultats de l'essai PIVOTAL ont servi à estimer l'augmentation prévue de la dose de fer IV et la réduction prévue de la dose d'ASE avec un protocole de fer IV à dose élevée. Nous avons supposé que la division entre les divers fabricants de fer IV et d'ASE était maintenue dans notre modèle de coûts. Les coûts totaux des médicaments ont été agrégés par unité d'hémodialyse, et les coûts moyens pour chaque unité ont été employés pour estimer les coûts par patient. Les analyses de sensibilité ont inclus des modèles qui supposaient une utilization à 100 % du fer saccharose IV et des modèles où les unités d'hémodialyse communautaires et hospitalières ont été examinées séparément. Enfin, nous avons calculé un seuil de rentabilité pour la réduction d'ASE nécessaire au maintien de la neutralité des coûts. RÉSULTATS: L'utilization réelle initiale de fer IV et d'ASE dans les 13 unités d'HD pour adultes était respectivement de 118 mg/patient/mois (IC 95 % : 102 mg à 134 mg) et de 20 764 UI/pt/mois (IC 95 % : 18 104 à 23 424 UI). Le coût combiné moyen du fer IV et des ASE était de 315 $/pt/mois (IC 95 % : 274 à 355 $). En comparaison, en utilisant les résultats de l'essai PIVOTAL et en supposant un scénario de fer IV à dose élevée, nous avons estimé une utilization moyenne de fer IV à 215 mg/pt/mois (IC 95 % : 187 à 243 mg/pt/mois) et une réduction de l'utilization moyenne d'ASE de 15 923 UI/pt/mois (IC 95 % : 13 883 à 17 962 UI/pt/mois); ce qui entraînerait une possible économie de 38 $/pt/mois (IC 95 % : 33 à 42 $/pt/mois) et une économie totale de 370 000 $ par année pour le program (IC 95 % : 325 000 à 420 000 $). Les analyses de sensibilité dans diverses conditions ont également montré des économies potentielles. Nous avons estimé qu'une réduction de 10 % de la dose d'ASE serait nécessaire pour maintenir la neutralité des coûts avec un protocole de fer IV à dose élevée. LIMITES: Notre étude utilize les données d'un seul essai clinique randomisé pour estimer les économies de coûts plutôt que l'utilization actualisée. Nos modèles ne prennent pas en compte les réductions dans les nombres de transfusions et d'hospitalisations qui pourraient découler d'un protocole de fer IV à dose élevée. CONCLUSION: Selon la modélisation des coûts, un protocole de fer IV à dose élevée pourrait être intégré à un program majeur d'hémodialyse régional canadien et réduire les coûts. Les programs qui mettent en œuvre un tel protocole devraient surveiller l'administration de fer IV et d'EPO de façon prospective pour déterminer si le protocole de l'essai, lorsqu'il est appliqué dans un contexte réel, se traduit par une réduction des coûts.

16.
Int J Stroke ; 16(7): 809-817, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-33232196

RESUMO

BACKGROUND: Timely identification of occult atrial fibrillation following cryptogenic stroke facilitates consideration of oral anticoagulation therapy. Extended electrocardiography monitoring beyond 24 to 48 h Holter monitoring improves atrial fibrillation detection rates, yet uncertainty remains due to upfront costs and the projected long-term benefit. We sought to determine the cost-effectiveness of three electrocardiography monitoring strategies in detecting atrial fibrillation after cryptogenic stroke. METHODS: A decision-analytic Markov model was used to project the costs and outcomes of three different electrocardiography monitoring strategies (i.e. 30-day electrocardiography monitoring, three-year implantable loop recorder monitoring, and conventional Holter monitoring) in acute stroke survivors without previously documented atrial fibrillation. RESULTS: The lifetime discounted costs and quality-adjusted life years were $206,385 and 7.77 quality-adjusted life years for conventional monitoring, $207,080 and 7.79 quality-adjusted life years for 30-day extended electrocardiography monitoring, and $210,728 and 7.88 quality-adjusted life years for the implantable loop recorder strategy. Additional quality-adjusted life years could be attained at a more favorable incremental cost per quality-adjusted life year with the implantable loop recorder strategy, compared with the 30-day electrocardiography monitoring strategy, thereby eliminating the 30-day strategy by extended dominance. The implantable loop recorder strategy was associated with an incremental cost per quality-adjusted life year gained of $40,796 compared with conventional monitoring. One-way sensitivity analyses indicated that the model was most sensitive to the rate of recurrent ischemic stroke. CONCLUSIONS: An implantable loop recorder strategy for detection of occult atrial fibrillation in patients with cryptogenic stroke is more economically attractive than 30-day electrocardiography monitoring compared to conventional monitoring and is associated with a cost per quality-adjusted life year gained in the range of other publicly funded therapies. The value proposition is improved when considering patients at the highest risk of recurrent ischemic stroke. However, the implantable loop recorder strategy is associated with increased health care costs, and the opportunity cost of wide scale implementation must be considered.


Assuntos
Fibrilação Atrial , AVC Isquêmico , Acidente Vascular Cerebral , Fibrilação Atrial/complicações , Fibrilação Atrial/diagnóstico , Análise Custo-Benefício , Eletrocardiografia , Eletrocardiografia Ambulatorial , Humanos , Acidente Vascular Cerebral/complicações , Acidente Vascular Cerebral/diagnóstico
17.
BMC Health Serv Res ; 20(1): 731, 2020 Aug 10.
Artigo em Inglês | MEDLINE | ID: mdl-32778102

RESUMO

BACKGROUND: Kidney failure requiring dialysis is associated with poor health outcomes and health-related quality of life (HRQL). Patient-reported outcome measures (PROMs) capture symptom burden, level of functioning and other outcomes from a patient perspective, and can support clinicians to monitor disease progression, address symptoms, and facilitate patient-centered care. While evidence suggests the use of PROMs in clinical practice can lead to improved patient experience in some settings, the impact on patients' health outcomes and experiences is not fully understood, and their cost-effectiveness in clinical settings is unknown. This study aims to fill these gaps by evaluating the effectiveness and cost-effectiveness of routinely measuring PROMs on patient-reported experience, clinical outcomes, HRQL, and healthcare utilization. METHODS: The EMPATHY trial is a pragmatic multi-centre cluster randomized controlled trial that will implement and evaluate the use of disease-specific and generic PROMs in three kidney care programs in Canada. In-centre hemodialysis units will be randomized into four groups, whereby patients: 1) complete a disease-specific PROM; 2) complete a generic PROM; 3) complete both types of PROMs; 4) receive usual care and do not complete any PROMs. While clinical care pathways are available to all hemodialysis units in the study, for the three active intervention groups, the results of the PROMs will be linked to treatment aids for clinicians and patients. The primary outcome of this study is patient-provider communication, assessed by the Communication Assessment Tool (CAT). Secondary outcomes include patient management and symptoms, use of healthcare services, and the costs of implementing this intervention will also be estimated. The present protocol fulfilled the Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) checklist. DISCUSSION: While using PROMs in clinical practice is supported by theory and rationale, and may engage patients and enhance their role in decisions regarding their care and outcomes, the best approach of their use is still uncertain. It is important to rigorously evaluate such interventions and investments to ensure they provide value for patients and health systems. TRIAL REGISTRATION: Protocol version (1.0) and trial registration data are available on www.clinicaltrials.gov , identifier: NCT03535922 , registered May 24, 2018.


Assuntos
Medidas de Resultados Relatados pelo Paciente , Diálise Renal , Canadá , Análise Custo-Benefício , Humanos , Aceitação pelo Paciente de Cuidados de Saúde , Qualidade de Vida , Diálise Renal/economia , Projetos de Pesquisa , Resultado do Tratamento
18.
Kidney Int ; 98(6): 1578-1588, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32619496

RESUMO

When multiple living donor candidates come forward to donate a kidney to the same recipient, some living donor programs evaluate one candidate at a time to avoid unnecessary evaluations. Evaluating multiple candidates concurrently rather than sequentially may be cost-effective from a societal perspective if it reduces the time recipients spend on dialysis. We used a simple decision tree to estimate the cost-effectiveness of evaluating two to four candidates simultaneously rather than sequentially as potential kidney donors for the same intended recipient. Evaluating two donor candidates simultaneously cost $1,266 (CAD) more than if they were evaluated sequentially, but living donation occurred one month earlier. This translated into $6,931 in averted dialysis costs and a total cost-savings of $5,665 per intended recipient. Simultaneous evaluations also resulted in one percent more living donor transplants and overall gains in quality-of-life as recipients spent less time on dialysis. If recipients were free from dialysis at the start of donor candidate evaluations, simultaneous evaluations also reduced the rate of dialysis initiation by two percent. Benefits were also observed in the three- and four-candidate scenarios. Thus, living donor programs should consider evaluating up to four living donor candidates simultaneously when they come forward for the same recipient as health care system costs incurred are more than offset by avoided dialysis costs.


Assuntos
Transplante de Rim , Doadores Vivos , Análise Custo-Benefício , Humanos , Rim , Transplante de Rim/economia , Diálise Renal
19.
Health Policy ; 124(4): 345-358, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32115252

RESUMO

Physician payment models are perceived to be an important strategy for improving health, access, quality, and the value of health care. Evidence is predominantly from primary care, and little is known regarding whether specialists respond similarly. We conducted a systematic review to synthesize evidence on the impact of specialist physician payment models across the domains of health care quality; clinical outcomes; utilization, access, and costs; and patient and physician satisfaction. We searched Medline, Embase, and six other databases from their inception through October 2018. Eligible articles addressed specialist physicians, payment models, outcomes of interest, and used an experimental or quasi-experimental design. Of 11,648 studies reviewed for eligibility, 11 articles reporting on seven payment reforms were included. Fee-for-service (FFS) was associated with increased desired utilization and fewer adverse outcomes (in the case of hemodialysis patients) and better access to care (in the case of emergency department services). Replacing FFS with capitation and salary models led to fewer elective surgical procedures (cataracts and tubal ligations) and, with an episode-based model, appeared to increase the use of less costly resources. Four of the seven reforms met their goals but many had unintended consequences. Payment model appears to affect utilization of specialty care, although the association with other outcomes is unclear due to mixed results or lack of evidence. Studies of salary and salary-based reforms point to specialists responding to some incentives differently than theory would predict. Additional research is warranted to improve the evidence driving specialist payment policy.


Assuntos
Planos de Pagamento por Serviço Prestado , Médicos , Humanos , Atenção Primária à Saúde , Qualidade da Assistência à Saúde , Salários e Benefícios
20.
CMAJ Open ; 8(1): E96-E104, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32071144

RESUMO

BACKGROUND: Health care payers are interested in policy-level interventions to increase peritoneal dialysis use in end-stage renal disease. We examined whether increases in physician remuneration for peritoneal dialysis were associated with greater peritoneal dialysis use. METHODS: We studied a cohort of patients in Alberta who started long-term dialysis with at least 90 days of preceding nephrologist care between Jan. 1, 2001, and Dec. 31, 2014. We compared peritoneal dialysis use 90 days after dialysis initiation in patients cared for by fee-for-service nephrologists and those cared for by salaried nephrologists before and after weekly peritoneal dialysis remuneration increased from $0 to $32 (fee change 1, Apr. 1, 2002), $49 to $71 (fee change 2, Apr. 1, 2007), and $71 to $135 (fee change 3, Apr. 1, 2009). Remuneration for peritoneal dialysis remained less than hemodialysis until fee change 3. We performed a patient-level differences-in-differences logistic regression, adjusted for demographic characteristics and comorbidities, as well as an unadjusted interrupted time-series analysis of monthly outcome data. RESULTS: Our cohort included 4262 patients. There was no statistical evidence of a difference in the adjusted differences-indifferences estimator following fee change 1 (0.89, 95% confidence interval [CI] 0.44-1.81), 2 (1.15, 95% CI 0.73-1.83), or 3 (1.52, 95% CI 0.96-2.40). There was no significant difference in the immediate change or the trend over time in peritoneal dialysis use between fee-for-service and salaried groups following any of the fee changes in the interrupted time-series analysis. INTERPRETATION: We identified no statistical evidence of an increase in peritoneal dialysis use following increased fee-for-service remuneration for peritoneal dialysis. It remains unclear what role, if any, physician payment plays in selection of dialysis modality.


Assuntos
Falência Renal Crônica/epidemiologia , Diálise Peritoneal/economia , Remuneração , Adulto , Idoso , Alberta/epidemiologia , Duração da Terapia , Planos de Pagamento por Serviço Prestado , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Médicos , Vigilância da População
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA